Clyde Biosciences Cardiomyocyte Assay
1 known investors
Clyde Biosciences is a contract research organization offering predictive cardiac safety and efficacy testing using human iPSC-derived cardiomyocyte models, aimed at pharmaceutical and biotech teams assessing cardiotoxicity for clinical translation. It provides functional cardiac safety data aligned with regulatory guidance, including the CiPA Assay.
Founders & leadership
GS
Godfrey SmithChief Scientific Officer and Co-Founder
FB
Francis BurtonHead of Software and Modeling & Co-Founder
RH
Richard HendersonChief Executive Officer
MB
Mark BryantChief Business Officer
Investors · 1
Competitors · 1
by search overlapCompanies competing with Clyde Biosciences Cardiomyocyte Assay for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Clyde Biosciences Cardiomyocyte Assay do?
- Clyde Biosciences is a contract research organization offering predictive cardiac safety and efficacy testing using human iPSC-derived cardiomyocyte models, aimed at pharmaceutical and biotech teams assessing cardiotoxicity for clinical translation. It provides functional cardiac safety data aligned with regulatory guidance, including the CiPA Assay.
- Who founded Clyde Biosciences Cardiomyocyte Assay?
- Clyde Biosciences Cardiomyocyte Assay was founded by Godfrey Smith, Francis Burton.
- Who are Clyde Biosciences Cardiomyocyte Assay's investors?
- Clyde Biosciences Cardiomyocyte Assay's investors include Epidarex Capital.